Merck KGaA (OTCMKTS:MKKGY - Get Free Report)'s share price was up 0.2% during trading on Wednesday . The company traded as high as $26.33 and last traded at $26.22. Approximately 156,967 shares were traded during trading, an increase of 33% from the average daily volume of 118,303 shares. The stock had previously closed at $26.16.
Merck KGaA Price Performance
The stock's fifty day moving average price is $26.50 and its 200-day moving average price is $27.78. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.83 and a current ratio of 1.31. The firm has a market cap of $16.94 billion, a PE ratio of 12.41, a P/E/G ratio of 1.95 and a beta of 0.92.
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.09. Merck KGaA had a net margin of 13.23% and a return on equity of 9.61%. The firm had revenue of $5.89 billion for the quarter, compared to analysts' expectations of $5.32 billion. As a group, equities analysts forecast that Merck KGaA will post 1.87 EPS for the current fiscal year.
Merck KGaA Increases Dividend
The business also recently announced a dividend, which was paid on Wednesday, May 7th. Investors of record on Wednesday, April 30th were given a $0.3382 dividend. The ex-dividend date of this dividend was Tuesday, April 29th. This is a boost from Merck KGaA's previous dividend of $0.32. This represents a dividend yield of 1.25%. Merck KGaA's dividend payout ratio (DPR) is currently 15.64%.
Merck KGaA Company Profile
(
Get Free Report)
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merck KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.
While Merck KGaA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
